Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:27:17 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:KZIA - KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
KZIA - Q0.60.35·0.390.20.3711+0.02617.6278.1833580.341  0.407  0.33511.64  0.186615:07:09Mar 2115 min RT 2¢

Recent Trades - Last 10 of 358
Time ETExPriceChangeVolume
15:07:09Q0.390.04384
15:06:51Q0.37110.02498
15:06:51Q0.37110.0261491
15:06:16Q0.38050.03551,000
14:49:42Q0.38050.0355500
14:47:26Q0.3850.038875
14:44:21Q0.3850.038894
14:41:49Q0.37680.03062
14:34:05Q0.38050.034310
14:33:15Q0.400.0551,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-21 08:52U:KZIANews ReleaseKazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
2024-03-13 08:00U:KZIANews ReleaseKazia announces presentation of new data at AACR Annual Meeting
2024-02-21 07:30U:KZIANews ReleaseKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
2024-01-18 07:30U:KZIANews ReleaseKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
2023-12-05 18:02U:KZIANews ReleaseKazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
2023-12-01 08:00U:KZIANews ReleaseKazia Therapeutics Announces $2 Million Registered Direct Offering
2023-11-29 07:01U:KZIANews ReleaseKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
2023-11-21 07:30U:KZIANews ReleaseKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
2023-11-20 16:30U:KZIANews ReleaseKAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
2023-11-15 08:30U:KZIANews ReleaseKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
2023-11-10 07:01U:KZIANews ReleaseKAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA
2023-11-01 07:01U:KZIANews ReleaseKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
2023-10-23 07:01U:KZIANews ReleaseKAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
2023-10-11 07:01U:KZIANews ReleaseKazia announces voluntary delisting from ASX
2023-10-05 07:01U:KZIANews ReleaseKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS
2023-09-29 07:01U:KZIANews ReleaseKAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
2023-07-06 07:00U:KZIANews ReleaseKAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
2023-06-08 07:00U:KZIANews ReleaseKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
2023-05-25 07:01U:KZIANews ReleaseKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT